Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom

Sarepta Therapeutics (NASDAQ: SRPT) has been halted ahead of today FDA AdCom to review the New Drug Application (NDA) for eteplirsen.

After plunging last Thursday on negative-biased FDA briefing documents, shares surged on Friday on positive draft questions.

You May Also Be Interested In

• Biogen's Empaveli cuts proteinuria 75% in teens with rare kidney disease
• Westinghouse said to seek over $50B valuation in U.S. IPO - Bloomberg
• U.S. Treasury Secretary to talk AI, rare earths this weekend with Chinese vice premier - AP